Maximum Tolerated Dose 4-16 months [clinicaltrials_resource:6fdf9e444123129eb1c4e3ef772cee33]
Reduction in the severity of the following B symptoms will be assessed: fever ≥ 101F, chills, night sweats, and anorexia with weight loss.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Maximum Tolerated Dose 4-16 months [clinicaltrials_resource:6fdf9e444123129eb1c4e3ef772cee33]
Reduction in the severity of the following B symptoms will be assessed: fever ≥ 101F, chills, night sweats, and anorexia with weight loss.
Bio2RDF identifier
6fdf9e444123129eb1c4e3ef772cee33
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:6fdf9e444123129eb1c4e3ef772cee33
measure [clinicaltrials_vocabulary:measure]
Maximum Tolerated Dose
time frame [clinicaltrials_vocabulary:time-frame]
4-16 months
description
Reduction in the severity of t ...... and anorexia with weight loss.
identifier
clinicaltrials_resource:6fdf9e444123129eb1c4e3ef772cee33
title
Maximum Tolerated Dose 4-16 months
@en
type
label
Maximum Tolerated Dose 4-16 mo ...... f9e444123129eb1c4e3ef772cee33]
@en